Synchroneuron secures $20 million in series B

Movement disorder company Synchroneuron Inc. (Waltham, Mass.) secured $20 million in a tranched series B round led by existing investor Morningside Technology Ventures. The company's SNC-102, a sustained-release formulation of acamprosate, is in Phase II testing for moderate to severe tardive dyskinesia, with top-line data expected early next year. The company said it plans to begin Phase II trials to evaluate the product to treat Tourette's syndrome and post-traumatic stress disorder (PTSD), but declined to disclose a timeline. ...